Cyclophosphamide and Alemtuzumab In Lymphoma

Clinical trial NCT03132584 · TERMINATED

Trial details

NCT number

NCT03132584

Sponsor

Dana-Farber Cancer Institute

Status

TERMINATED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2017-07-30

Primary completion

2018-01-30

Enrollment

3

View on ClinicalTrials.gov